Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Université Paris Descartes

Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris

Université De Paris

Inserm

Georgia Afonso

Roberto Mallone

Slobodan Culina

Sergio Gonzalez-duque

Ana Ines Lalanne

Marie-Eliane Azoury

Yann Verdier

Joëlle Vinh

Despite the notion that human CD8T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naive CD8T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.

Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes

The present invention relates to T-cell receptors (TCR) that recognize pancreatic betacell epitopes and uses thereof for the diagnosis and treatment of diabetes.

T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes

The present invention relates to methods for stimulating antigen-specific T cell responses. In particular, the invention relates to a method for stimulating antigen (Ag)-specific T cell responses in a blood sample or PBMC sample isolated from a subject comprising the step consisting in culturing said blood or PBMC sample in a appropriate culture medium which comprises an amount of IL-1beta and an amount of a least one antigen.

Methods for stimulating antigen-specific T cell responses

Growing community of inventors

Paris, France

Georgia Afonso